LIGAND PHARMA (LGDN.SG)
LIGAND PHARMA (LGDN.SG) operates in Diversified Metals & Mining.
LIGAND PHARMA (LGDN.SG) (LGDN) - Net Assets
Latest net assets as of September 2024: €841.18 Million EUR
Based on the latest financial reports, LIGAND PHARMA (LGDN.SG) (LGDN) has net assets worth €841.18 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€954.87 Million) and total liabilities (€113.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €841.18 Million |
| % of Total Assets | 88.09% |
| Annual Growth Rate | 10.83% |
| 5-Year Change | -8.64% |
| 10-Year Change | N/A |
| Growth Volatility | 22.02 |
LIGAND PHARMA (LGDN.SG) - Net Assets Trend (2016–2023)
This chart illustrates how LIGAND PHARMA (LGDN.SG)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LIGAND PHARMA (LGDN.SG) (2016–2023)
The table below shows the annual net assets of LIGAND PHARMA (LGDN.SG) from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €700.91 Million | +17.31% |
| 2022-12-31 | €597.49 Million | -27.24% |
| 2021-12-31 | €821.16 Million | +15.73% |
| 2020-12-31 | €709.52 Million | -7.52% |
| 2019-12-31 | €767.23 Million | +36.78% |
| 2018-12-31 | €560.91 Million | +40.30% |
| 2017-12-31 | €399.79 Million | +17.14% |
| 2016-12-31 | €341.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LIGAND PHARMA (LGDN.SG)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 93414300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €503.02 Million | 71.77% |
| Other Components | €197.90 Million | 28.23% |
| Total Equity | €700.91 Million | 100.00% |
LIGAND PHARMA (LGDN.SG) Competitors by Market Cap
The table below lists competitors of LIGAND PHARMA (LGDN.SG) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haidemenos S.A.
AT:HAIDE
|
$1.82 Million |
|
Raise Production Inc
PINK:GLKFF
|
$1.82 Million |
|
The Singing Machine Company Inc. Common Stock
NASDAQ:MICS
|
$1.82 Million |
|
KUEHNE+NAGEL INT N
MU:KNIA
|
$1.82 Million |
|
Superior Industries International
NYSE:SUP
|
$1.81 Million |
|
Kanani Industries Limited
NSE:KANANIIND
|
$1.81 Million |
|
Generation Income Properties Inc
NASDAQ:GIPR
|
$1.81 Million |
|
Mathios Refractories S.A.
AT:MATHIO
|
$1.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIGAND PHARMA (LGDN.SG)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 597,485,000 to 700,913,000, a change of 103,428,000 (17.3%).
- Net income of 52,154,000 contributed positively to equity growth.
- Other factors increased equity by 51,274,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €52.15 Million | +7.44% |
| Other Changes | €51.27 Million | +7.32% |
| Total Change | €- | 17.31% |
Book Value vs Market Value Analysis
This analysis compares LIGAND PHARMA (LGDN.SG)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.00x to 4.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €18.90 | €189.00 | x |
| 2018-12-31 | €27.01 | €189.00 | x |
| 2019-12-31 | €45.61 | €189.00 | x |
| 2020-12-31 | €44.12 | €189.00 | x |
| 2021-12-31 | €48.97 | €189.00 | x |
| 2022-12-31 | €35.25 | €189.00 | x |
| 2023-12-31 | €39.92 | €189.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LIGAND PHARMA (LGDN.SG) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.44%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 39.72%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.12x
- Recent ROE (7.44%) is below the historical average (14.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -0.48% | -1.50% | 0.18x | 1.76x | €-35.77 Million |
| 2017 | 3.14% | 8.90% | 0.21x | 1.68x | €-27.42 Million |
| 2018 | 25.55% | 57.00% | 0.20x | 2.25x | €87.23 Million |
| 2019 | 82.02% | 523.19% | 0.08x | 1.95x | €552.58 Million |
| 2020 | -0.42% | -1.82% | 0.12x | 1.92x | €-73.94 Million |
| 2021 | 6.96% | 23.66% | 0.19x | 1.58x | €-24.98 Million |
| 2022 | -5.58% | -17.00% | 0.26x | 1.28x | €-93.11 Million |
| 2023 | 7.44% | 39.72% | 0.17x | 1.12x | €-17.94 Million |
Industry Comparison
This section compares LIGAND PHARMA (LGDN.SG)'s net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIGAND PHARMA (LGDN.SG) (LGDN) | €841.18 Million | -0.48% | 0.14x | $1.81 Million |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |